Published in Cancer Weekly, June 2nd, 2009
The corrected release reads: DATA FROM THE PHASE III SATURN STUDY SHOW TARCEVA IMPROVED PROGRESSION-FREE SURVIVAL WHEN USED AS A FIRST-LINE MAINTENANCE THERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER -- Data Showed Tarceva Improved PFS in Patients with Both Non-Squamous Cell Carcinoma and Squamous Cell Carcinoma -- Patients with an EGFR Mutation Achieved a 10 Fold...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.